Peptides

Tesamorelin: FDA-Approved GH Peptide — Dosage, Benefits, and Uses

Medically reviewed by Medical Advisory Board Last reviewed 2026-05-13

The only FDA-approved GHRH analog for visceral fat reduction — and what that means for off-label use

Tesamorelin (Egrifta) is an FDA-approved GHRH analog with the strongest clinical evidence base of any growth hormone peptide. Originally approved for HIV-associated lipodystrophy, it's increasingly used off-label for visceral fat reduction and GH optimization.

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone that was FDA-approved in 2010 for HIV-associated lipodystrophy — a condition where antiretroviral medications cause problematic visceral fat accumulation. It has the most robust clinical evidence base of any GHRH peptide, with multiple Phase III randomized controlled trials in humans.

Tesamorelin reduces visceral adipose tissue significantly more than any other GHRH-class peptide in head-to-head clinical comparisons. While its FDA approval is narrow (HIV lipodystrophy), it's increasingly used off-label in anti-aging and functional medicine for visceral fat reduction and growth hormone optimization.

Want expert help with your metabolic health?

We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.

Book An Appointment With A Specialist →

What Is Tesamorelin Peptide?

Tesamorelin peptide is a stabilized analog of growth hormone-releasing hormone (GHRH). It tells the pituitary to release growth hormone in pulses, which then raises IGF-1 and can shift body composition. Unlike synthetic HGH, tesamorelin does not replace growth hormone directly; it stimulates the body's own GH axis.

The phrase matters because many people compare tesamorelin with other peptide therapy options such as sermorelin, CJC-1295, ipamorelin, and HGH fragment. Tesamorelin is the most clinically validated GHRH analog for visceral fat reduction, but it is also more expensive and has a narrower FDA-approved indication than most people realize.

Tesamorelin Clinical Evidence

Key clinical findings from FDA-registration trials and post-market research:

Visceral fat reduction: 15–25% reduction in visceral adipose tissue (VAT) in 26-week trials vs. placebo. Statistically significant in multiple RCTs.
IGF-1 elevation: Dose-dependent IGF-1 increases of approximately 100 ng/mL from baseline.
Lipid effects: Reduction in triglycerides (~15%) and total cholesterol in some studies.
Cognitive effects: A randomized trial in older adults without HIV showed improved executive function and verbal memory with tesamorelin vs. placebo (Baker et al., 2012, JAMA Neurology).
Body composition: Modest increases in lean mass alongside visceral fat reduction.

Tesamorelin Dosage

FDA-approved dosing (HIV lipodystrophy) and off-label protocols:

FDA-approved dose: 2 mg subcutaneously once daily
Off-label (anti-aging/visceral fat): 1–2 mg subcutaneously daily
Administration: Subcutaneous injection, abdomen; rotate sites
Monitoring: IGF-1 levels at 3 months; target upper-normal range for age

Tesamorelin vs Sermorelin: Key Differences

Factor	Tesamorelin	Sermorelin
Half-life	~26 minutes	~12 minutes
FDA status	Approved (HIV lipodystrophy)	Approved (GH deficiency, children)
Clinical evidence	Multiple Phase III RCTs	Decades of off-label clinical use
Visceral fat reduction	Superior (primary endpoint in trials)	Present but less studied
Cost	Very high (brand: $3,000–5,000/mo)	$150–400/mo (compounded)
Typical use	Daily standalone	Daily, often stacked with GHRP

Frequently Asked Questions

What is tesamorelin?

Tesamorelin (Egrifta) is an FDA-approved synthetic GHRH analog used clinically for HIV-associated lipodystrophy. It stimulates pituitary GH release and is particularly effective at reducing visceral adipose tissue — the dangerous fat around organs linked to cardiovascular disease and metabolic syndrome. It has the strongest clinical evidence base of any GHRH peptide.

What is the tesamorelin dosage?

The FDA-approved dose for HIV lipodystrophy is 2 mg subcutaneously daily. Off-label anti-aging protocols typically use 1–2 mg daily. Monitoring IGF-1 at 3 months is recommended to ensure levels are in the age-appropriate optimal range without exceeding safe limits.

Tesamorelin vs sermorelin — which is better?

Tesamorelin has stronger clinical evidence (Phase III RCTs) and superior visceral fat reduction. Sermorelin has decades of off-label clinical use, is far cheaper ($150–400/mo compounded vs. $3,000–5,000/mo for brand tesamorelin), and is more widely available. For most people outside an HIV-lipodystrophy diagnosis, sermorelin or CJC-1295/ipamorelin provides similar GH optimization at a fraction of the cost.

Topic updates

Get the weekly peptide roundup

Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

Check Where You Stand

Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results